Middle East Healthcare Future Growth
Future criteria checks 4/6
Middle East Healthcare is forecast to grow earnings and revenue by 22% and 10% per annum respectively. EPS is expected to grow by 21% per annum. Return on equity is forecast to be 17.8% in 3 years.
Key information
22.0%
Earnings growth rate
21.0%
EPS growth rate
| Healthcare earnings growth | 14.8% |
| Revenue growth rate | 10.0% |
| Future return on equity | 17.8% |
| Analyst coverage | Good |
| Last updated | 08 Aug 2024 |
Recent future growth updates
Middle East Healthcare Company (TADAWUL:4009) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 09
Middle East Healthcare Company Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 09Recent updates
Middle East Healthcare Company (TADAWUL:4009) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 09Middle East Healthcare Company's (TADAWUL:4009) Price In Tune With Earnings
Jul 18There's Been No Shortage Of Growth Recently For Middle East Healthcare's (TADAWUL:4009) Returns On Capital
May 30Middle East Healthcare Company Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 09If EPS Growth Is Important To You, Middle East Healthcare (TADAWUL:4009) Presents An Opportunity
Apr 29Why Investors Shouldn't Be Surprised By Middle East Healthcare Company's (TADAWUL:4009) 27% Share Price Plunge
Apr 02There's Reason For Concern Over Middle East Healthcare Company's (TADAWUL:4009) Massive 40% Price Jump
Feb 11Returns On Capital At Middle East Healthcare (TADAWUL:4009) Have Stalled
Feb 08Should You Be Adding Middle East Healthcare (TADAWUL:4009) To Your Watchlist Today?
Jan 18Middle East Healthcare Company's (TADAWUL:4009) Revenues Are Not Doing Enough For Some Investors
Dec 28Middle East Healthcare (TADAWUL:4009) Will Want To Turn Around Its Return Trends
Sep 26Some Investors May Be Worried About Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Jun 28Investors Could Be Concerned With Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Mar 30Capital Allocation Trends At Middle East Healthcare (TADAWUL:4009) Aren't Ideal
Sep 20Calculating The Intrinsic Value Of Middle East Healthcare Company (TADAWUL:4009)
Jun 14Returns On Capital At Middle East Healthcare (TADAWUL:4009) Paint A Concerning Picture
Apr 18Here's What's Concerning About Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Aug 10Middle East Healthcare (TADAWUL:4009) Will Will Want To Turn Around Its Return Trends
Mar 29An Intrinsic Calculation For Middle East Healthcare Company (TADAWUL:4009) Suggests It's 28% Undervalued
Mar 03Are Middle East Healthcare's (TADAWUL:4009) Statutory Earnings A Good Guide To Its Underlying Profitability?
Feb 10Weak Financial Prospects Seem To Be Dragging Down Middle East Healthcare Company (TADAWUL:4009) Stock
Jan 23If You Had Bought Middle East Healthcare's (TADAWUL:4009) Shares Three Years Ago You Would Be Down 38%
Jan 05Should You Be Impressed By Middle East Healthcare's (TADAWUL:4009) Returns on Capital?
Dec 18Calculating The Fair Value Of Middle East Healthcare Company (TADAWUL:4009)
Nov 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3,696 | 380 | 314 | 443 | 6 |
| 12/31/2025 | 3,338 | 313 | 202 | 455 | 7 |
| 12/31/2024 | 2,932 | 232 | 28 | 433 | 1 |
| 6/30/2024 | 2,793 | 203 | 87 | 274 | N/A |
| 3/31/2024 | 2,704 | 182 | 69 | 270 | N/A |
| 12/31/2023 | 2,653 | 180 | -41 | 191 | N/A |
| 9/30/2023 | 2,551 | 177 | 72 | 402 | N/A |
| 6/30/2023 | 2,393 | 135 | 113 | 466 | N/A |
| 3/31/2023 | 2,276 | 105 | -95 | 172 | N/A |
| 12/31/2022 | 2,152 | 75 | -174 | 76 | N/A |
| 9/30/2022 | 2,033 | 24 | -292 | 9 | N/A |
| 6/30/2022 | 2,019 | 27 | -309 | 1 | N/A |
| 3/31/2022 | 1,968 | 26 | -259 | 114 | N/A |
| 12/31/2021 | 1,873 | 17 | -341 | 77 | N/A |
| 9/30/2021 | 1,823 | 45 | -434 | -37 | N/A |
| 6/30/2021 | 1,816 | 66 | -580 | -160 | N/A |
| 3/31/2021 | 1,733 | 73 | -501 | -166 | N/A |
| 12/31/2020 | 1,751 | 82 | -524 | -229 | N/A |
| 9/30/2020 | 1,708 | 110 | -507 | -182 | N/A |
| 6/30/2020 | 1,603 | 108 | -348 | -23 | N/A |
| 3/31/2020 | 1,583 | 104 | -440 | -38 | N/A |
| 12/31/2019 | 1,497 | 98 | -373 | 99 | N/A |
| 9/30/2019 | 1,401 | 91 | -351 | 133 | N/A |
| 6/30/2019 | 1,353 | 78 | -335 | 180 | N/A |
| 3/31/2019 | 1,346 | 100 | -289 | 164 | N/A |
| 12/31/2018 | 1,391 | 172 | -197 | 159 | N/A |
| 9/30/2018 | 1,445 | 224 | -39 | 317 | N/A |
| 6/30/2018 | 1,459 | 269 | -61 | 204 | N/A |
| 3/31/2018 | 1,464 | 297 | N/A | 135 | N/A |
| 12/31/2017 | 1,462 | 319 | N/A | 347 | N/A |
| 9/30/2017 | 1,503 | 322 | N/A | 370 | N/A |
| 6/30/2017 | 1,529 | 356 | N/A | 256 | N/A |
| 3/31/2017 | 1,588 | 368 | N/A | 453 | N/A |
| 12/31/2016 | 1,616 | 363 | N/A | 253 | N/A |
| 9/30/2016 | 1,629 | 380 | N/A | 72 | N/A |
| 6/30/2016 | 1,602 | 371 | N/A | 313 | N/A |
| 3/31/2016 | 1,564 | 389 | N/A | 303 | N/A |
| 12/31/2015 | 1,535 | 390 | N/A | 194 | N/A |
| 9/30/2015 | 1,485 | 373 | N/A | 434 | N/A |
| 6/30/2015 | 1,456 | 356 | N/A | 383 | N/A |
| 3/31/2015 | 1,431 | 357 | N/A | 253 | N/A |
| 12/31/2014 | 1,399 | 332 | N/A | 349 | N/A |
| 12/31/2013 | 828 | 137 | N/A | 129 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4009's forecast earnings growth (22% per year) is above the savings rate (14.5%).
Earnings vs Market: 4009's earnings (22% per year) are forecast to grow faster than the SA market (7% per year).
High Growth Earnings: 4009's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 4009's revenue (10% per year) is forecast to grow faster than the SA market (0.9% per year).
High Growth Revenue: 4009's revenue (10% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4009's Return on Equity is forecast to be low in 3 years time (17.8%).